Johnson & Samuel Johnson Wins U.S. Approval for Expanded Remicade Use Bloomberg Remicade was approved in 1998 as the archetypal anti-tumor necrosis factor (TNF)-alpha treatment in the United States of America It is used in Crohn's disease in adults and children, and ulcerative colitis, rheumatoid arthritis and psoriasis in adults. ... REMICADE® Receives FDA approving as First Biologic attention for Pediatric ... MarketWatch (press release) J&J's Remicade approved for new medicine use Forbes all xxii news articles » Link To Article
No comments:
Post a Comment